Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 21, 2026, 7:41 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–17 of 17 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Refractory Ascites Clear all
Recruiting Phase 2 Interventional

High Dose Albumin in Refractory Ascites

NCT05867602
View directory record Official record
Conditions
Ascites
Interventions
Albumin
Drug
Lead sponsor
Baylor College of Medicine
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2027
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jun 29, 2026 · Synced Jul 21, 2026, 7:41 PM EDT
Completed Phase 3 Interventional

North American Study for the Treatment of Refractory Ascites (NASTRA)

NCT00006166
View directory record Official record
Conditions
Ascites, Liver Cirrhosis
Interventions
Transjugular intrahepatic portasystemic shunts (TIPS), Total paracentecis (TP)
Procedure
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
18 Years to 70 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
1997 – 2001
U.S. locations
5
States / cities
Miami, Florida • Omaha, Nebraska • Portland, Oregon + 2 more
Source: ClinicalTrials.gov public record
Updated Jan 12, 2010 · Synced Jul 21, 2026, 7:41 PM EDT
Recruiting No phase listed Observational

QOL and Sarcopenia in Patients With Ascites

NCT05726747
View directory record Official record
Conditions
Ascites Hepatic, Ascites, Malignant
Interventions
Quality of Life surveys
Diagnostic Test
Lead sponsor
Abramson Cancer Center at Penn Medicine
Other
Eligibility
18 Years and older
Enrollment
70 participants
Timeline
2023 – 2027
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 14, 2026 · Synced Jul 21, 2026, 7:41 PM EDT
Recruiting Phase 1 Interventional

Single and Multiple Dose Escalation of PHIN-214 in Child-Pugh A and B Liver Cirrhotics

NCT05490888
View directory record Official record
Conditions
Cirrhosis, Liver, Liver Fibrosis, Ascites Hepatic
Interventions
PHIN-214 Subcutaneous injection
Drug
Lead sponsor
PharmaIN
Industry
Eligibility
18 Years to 75 Years
Enrollment
74 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
9
States / cities
Chandler, Arizona • Coronado, California • Marrero, Louisiana + 5 more
Source: ClinicalTrials.gov public record
Updated Sep 4, 2025 · Synced Jul 21, 2026, 7:41 PM EDT
Withdrawn Not applicable Interventional

HepQuant to Predict Hepatic Encephalopathy After TIPS

NCT04664621
View directory record Official record
Conditions
Hepatic Encephalopathy, Cirrhosis, Liver
Interventions
HepQuant
Diagnostic Test
Lead sponsor
Northwestern University
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Aug 8, 2022 · Synced Jul 21, 2026, 7:41 PM EDT
Terminated No phase listed Observational

Glutamine Challenge as Predictor of Hepatic Encephalopathy After Transjugular Intrahepatic Portosystemic Shunt (TIPS)

NCT02026609
View directory record Official record
Conditions
Refractory Ascites, Hepatic Hydrothorax, Hepatic Encephalopathy, Cirrhosis
Interventions
Oral glutamine challenge, Psychometric Tests
Other
Lead sponsor
University of Arkansas
Other
Eligibility
18 Years to 75 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
Little Rock, Arkansas
Source: ClinicalTrials.gov public record
Updated Apr 16, 2017 · Synced Jul 21, 2026, 7:41 PM EDT
Terminated Phase 2 Interventional

A Study for Evaluation of BIV201 to Reduce Ascites and Complications in Patients With Cirrhosis and Refractory Ascites

NCT04112199
View directory record Official record
Conditions
Ascites, Decompensated Cirrhosis
Interventions
BIV201 continuous infusion
Drug
Lead sponsor
BioVie Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
10
States / cities
Los Angeles, California • Jacksonville, Florida • Miami, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated May 7, 2024 · Synced Jul 21, 2026, 7:41 PM EDT
Completed Not applicable Interventional

Impact of Palliative Catheter Placement on the Quality of Life of Patients With Refractory Ascites

NCT01188746
View directory record Official record
Conditions
Ascites
Interventions
McGill Quality of Life Questionnaire and the European Organization for Research and Treatment of Cancer Quality of Life Core Questionnaire
Behavioral
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2020
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 5, 2020 · Synced Jul 21, 2026, 7:41 PM EDT
Completed Not applicable Interventional

Evaluation of Hemodynamic Parameters Following Transjugular Intrahepatic Portosystemic Shunt (TIPS)

NCT04050683
View directory record Official record
Conditions
Refractory Ascites
Interventions
Study - Transjugular Intrahepatic Portosystemic Shunt (TIPS), Control - Transjugular Intrahepatic Portosystemic Shunt (TIPS)
Procedure
Lead sponsor
Medical College of Wisconsin
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
1
States / cities
Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Dec 12, 2024 · Synced Jul 21, 2026, 7:41 PM EDT
Completed Not applicable Interventional

A (M)Ulti-center, Prospective, (O)Pen Label, Uncontrolled Feasibility (S)Tudy to Assess the Safety and Effectiveness of an Automatic Low Flow (A)Scites (Alfa) Pump (I)n Patients With (C)Irrhosis and Refractory or Recurrent Ascites

NCT02400164
View directory record Official record
Conditions
Cirrhosis, Ascites
Interventions
alfapump system
Device
Lead sponsor
Sequana Medical N.V.
Industry
Eligibility
21 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
5
States / cities
San Francisco, California • Rochester, Minnesota • Dallas, Texas + 2 more
Source: ClinicalTrials.gov public record
Updated Apr 5, 2018 · Synced Jul 21, 2026, 7:41 PM EDT
Completed Phase 1 Interventional

Empagliflozin in Diuretic Refractory Ascites

NCT05013502
View directory record Official record
Conditions
Liver Cirrhosis, Cirrhosis, Ascites, Ascites Hepatic, Sodium-Glucose Transporter 2 Inhibitors
Interventions
Empagliflozin 10 MG
Drug
Lead sponsor
Stanford University
Other
Eligibility
18 Years to 75 Years
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Redwood City, California
Source: ClinicalTrials.gov public record
Updated Aug 1, 2023 · Synced Jul 21, 2026, 7:41 PM EDT
Terminated Phase 1 Interventional

Feasibility Study of Intraperitoneal Bevacizumab for Palliation of Intractable Malignant Ascites

NCT02496286
View directory record Official record
Conditions
Malignant Ascites
Interventions
Intraperitoneal Bevacizumab
Drug
Lead sponsor
Eastern Regional Medical Center
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 11, 2017 · Synced Jul 21, 2026, 7:41 PM EDT
Terminated Phase 2 Interventional Results available

Trial of Sunitinib for Refractory Malignant Ascites

NCT00796861
View directory record Official record
Conditions
Ascites
Interventions
Sunitinib
Drug
Lead sponsor
Milton S. Hershey Medical Center
Other
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
1
States / cities
Hershey, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Dec 19, 2017 · Synced Jul 21, 2026, 7:41 PM EDT
Completed Phase 2 Interventional Results available

Continuous Infusion Terlipressin for Patients With Cirrhosis and Refractory Ascites

NCT03107091
View directory record Official record
Conditions
Cirrhosis, Ascites Hepatic
Interventions
Terlipressin acetate continuous infusion
Drug
Lead sponsor
BioVie Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated Jul 12, 2021 · Synced Jul 21, 2026, 7:41 PM EDT
Terminated Phase 1Phase 2 Interventional Results available

Phase 1/2a Two-Arm Dose-Escalation Study of BAX69 in Subjects With Malignant Ascites of Ovarian Cancer

NCT02540356
View directory record Official record
Conditions
Refractory Ovarian Cancer With Recurrent Symptomatic Malignant Ascites
Interventions
BAX69 Single-Route Arm, BAX69 Double-Route Arm
Biological
Lead sponsor
Baxalta now part of Shire
Industry
Eligibility
18 Years and older · Female only
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
6
States / cities
Miami, Florida • Augusta, Georgia • Silver Spring, Maryland + 3 more
Source: ClinicalTrials.gov public record
Updated Jan 11, 2021 · Synced Jul 21, 2026, 7:41 PM EDT
Withdrawn No phase listed Observational

Palliative Care Outcomes in the Management of Malignant Ascites by Interventional Radiology

NCT02477657
View directory record Official record
Conditions
Refractory Malignant Ascites
Interventions
Paracentesis, Tunneled Intraperitoneal Drain (IPD), Peritoneal-Venous shunts (PVS)
Procedure · Device
Lead sponsor
Abramson Cancer Center at Penn Medicine
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 11, 2022 · Synced Jul 21, 2026, 7:41 PM EDT
Active, not recruiting Not applicable Interventional

Alfapump® System in the Treatment of Refractory or Recurrent Ascites (POSEIDON Study)

NCT03973866
View directory record Official record
Conditions
Ascites
Interventions
Alfapump
Device
Lead sponsor
Sequana Medical N.V.
Industry
Eligibility
18 Years and older
Enrollment
110 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
13
States / cities
Phoenix, Arizona • Los Angeles, California • Worcester, Massachusetts + 9 more
Source: ClinicalTrials.gov public record
Updated Nov 30, 2022 · Synced Jul 21, 2026, 7:41 PM EDT